I would actually love to hear what @lcj thinks of this, as she's a biostatistician in the clinical trials space.To take a group of people with NIHL and give some of them the drug and some of them a sugar pill and then see what happens. Makes sense.
@lcj, can you ELI5, do you think the $50M-100M cost for Hough Ear Institute's phase 2 is par for the course? And what is your opinion on clinical trials generally? Could the system be more streamlined, saving money, time, and getting drugs faster for those in need? Is there any positive movement in the field that you'd like to note? And finally, what should a layperson do if they want quicker access to drugs in testing phases?
I did find the following:
"When we look at different therapeutic areas in Table 1, we see that the average cost of a Phase 2 clinical trial ranges from $7.0 million to $19.6 million, while the average costs of phase 3 clinical trials range from $11.5 million to $52.9 million."
(source)
So I guess the $50M-100M estimate for the phase 2 seems a bit high, but we can surely explore this subject in the interview. In any case it will be interesting to get Hough Ear Institute's viewpoints on clinical trials, how much leaner / affordable could they be made if there was a little less bureaucracy, etc...
We are looking forward to get the interview out ASAP!